Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT04963283 |
TitleStudy of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer | 阶段
第二阶段
|
Date Added 2021-07-15 |
地点
Colorado, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Cabozantinib, Nivolumab |
标签
MSS/ MMRp
|
| NCT ID NCT04948034 |
Title转移性结直肠癌中的福格替尼、替利珠单抗和立体定向消融放疗联合疗法（RIFLE） | 阶段
第二阶段
|
Date Added 2021-07-01 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Fruquintinib, Tislelizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04940546 |
TitleNeoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patients | 阶段
Phase 1, Phase 2
|
Date Added 2021-06-25 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Bevacizumab, capecitabine, oxaliplatin, Sintilimab |
标签
MSS/ MMRp
|
| NCT ID NCT04895709 |
Title一项针对晚期实体瘤患者的BMS-986340单药及与Nivolumab联合用药研究 | 阶段
Phase 1, Phase 2
|
Date Added 2021-05-20 |
地点
California, United States
Iowa, United States New Jersey, United States New York, United States Oregon, United States Tennessee, United States Texas, United States 澳大利亚 加拿大 德国 以色列 意大利 日本 西班牙 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
BMS-936558-01, BMS-986340 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04895722 |
TitleEvaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008) | 阶段
第二阶段
|
Date Added 2021-05-20 |
地点
Florida, United States
Georgia, United States Illinois, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Washington, United States 比利时 加拿大 Colombia Costa Rica 丹麦 Estonia 法国 德国 希腊 Guatemala Hungary 意大利 大韩民国 Lithuania 荷兰 波兰 Romania Russian Federation 西班牙 Turkey 英国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Favezelimab/Pembrolizumab, Pembrolizumab/Quavonlimab, pembrolizumab/vibostolimab coformulation, Keytruda |
标签
MSI-H/ MMRd
|
| NCT ID NCT04874259 |
TitleLT治疗无法切除的结直肠肝转移瘤 | 阶段
不适用
|
Date Added 2021-05-05 |
地点
大韩民国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04866862 |
TitleFruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer | 阶段
第二阶段
|
Date Added 2021-04-30 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Combination of Fruquintinib and Camrelizumab |
标签
MSS/ MMRp
|
| NCT ID NCT04853017 |
TitleELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201) | 阶段
第 1 阶段
|
Date Added 2021-04-21 |
地点
California, United States
Colorado, United States Iowa, United States Massachusetts, United States Missouri, United States New York, United States Tennessee, United States Texas, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04793958 |
TitleKRAS G12C突变晚期结直肠癌患者MRTX849联合西妥昔单抗与化疗的3期研究（KRYSTAL-10） | 阶段
第三阶段
|
Date Added 2021-03-11 |
地点
Alabama, United States
Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States West Virginia, United States Wisconsin, United States 阿根廷 澳大利亚 Austria 比利时 巴西 加拿大 中国 Colombia Czechia 丹麦 Finland 法国 德国 希腊 香港 Ireland 意大利 大韩民国 Malaysia 墨西哥 荷兰 波兰 葡萄牙 波多黎各 Romania 新加坡 西班牙 台湾 泰国 Ukraine 英国 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
cetuximab, FOLFIRI Regimen, mFOLFOX6 Regimen, MRTX849 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04776148 |
TitleStudy of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) | 阶段
第三阶段
|
Date Added 2021-03-01 |
地点
California, United States
Georgia, United States Illinois, United States Maryland, United States Michigan, United States Montana, United States Oregon, United States Pennsylvania, United States Virginia, United States Washington, United States 阿根廷 澳大利亚 加拿大 中国 丹麦 德国 以色列 日本 大韩民国 Russian Federation 西班牙 台湾 Turkey 英国 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Lenvatinib, Pembrolizumab, Regorafenib, TAS-102 (trifluridine and tipiracil) |
标签
MSS/ MMRp
|
